Premium
Mineralocorticoid receptor blockade does not improve vascular endothelial function in older adults with metabolic syndrome
Author(s) -
Hwang MoonHyon,
Yoo JeungKi,
Luttrell Meredith J.,
Cernosek Molly M.,
Meade Thomas H.,
English Mark W,
Christou Demetra D.
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.821.45
Aging and metabolic syndrome (MS) are associated with impaired endothelium‐dependent dilation (EDD) but the underlying mechanisms are not completely understood. We hypothesized that mineralocorticoid receptor (MR) blockade would lead to greater improvements in flow‐mediated dilation (% change in brachial artery diameter after reactive hyperemia using ultrasonography; FMD) in older adults with vs. without MS. To test this hypothesis, we administered 100 mg of Eplerenone (MR blocker) or placebo per day for 4 weeks in a randomized, double blind, crossover design, in 8 older adults (4 men & 4 women) with and 7 older adults (2 men & 5 women) without MS. In older adults with MS, FMD did not change (5.37±0.85 vs. 5.98±1.29%, P=0.4, placebo vs. blockade). In older adults without MS, FMD decreased by 17%, although this change did not reach statistical significance (7.69±1.4 vs. 6.37±1.5%, P=0.093, placebo vs. blockade). In the whole group, a greater increase in FMD was associated with higher MS z score (r=0.55, P=0.03), baseline fasting glucose (r=0.56, P=0.03), total % body fat (r=0.77, P=0.001), abdominal subcutaneous fat (r=0.75, P=0.005) and abdominal visceral fat (r=0.68, P=0.01). In conclusion, MR blockade does not improve EDD in older adults with or without MS. Greater improvements in EDD are associated with elevated fasting glucose and increased adiposity. Supported by AHA Grant 0865117F and NIH Grant AG032067.